[{"id":"1356603e-b2dd-488c-b74a-f432af18b9a1","acronym":"DDRiver Solid Tumours 301","url":"https://clinicaltrials.gov/study/NCT04170153","created_at":"2021-06-11T21:52:37.231Z","updated_at":"2025-02-25T12:27:22.944Z","phase":"Phase 1","brief_title":"Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)","source_id_and_acronym":"NCT04170153 - DDRiver Solid Tumours 301","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" ARID1A • ATRX","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ARID1A • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • tuvusertib (M1774)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 161","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-24"},{"id":"a3ff3bf1-6fbc-4e00-b8e0-454d7fb78cce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687136","created_at":"2023-01-18T15:59:53.342Z","updated_at":"2025-02-25T13:41:23.007Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors","source_id_and_acronym":"NCT05687136","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"a68faa2b-d426-44af-a80f-b0fc99a1c7cd","acronym":"NXP800-101","url":"https://clinicaltrials.gov/study/NCT05226507","created_at":"2023-04-14T16:03:28.481Z","updated_at":"2025-02-25T15:12:35.833Z","phase":"Phase 1","brief_title":"A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer","source_id_and_acronym":"NCT05226507 - NXP800-101","lead_sponsor":"Nuvectis Pharma, Inc.","biomarkers":" ARID1A • BRCA","pipe":" | ","alterations":" ARID1A mutation • BRCA mutation","tags":["ARID1A • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NXP800"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-13"},{"id":"757c7ea9-28ea-4973-bbc9-a09748839d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039801","created_at":"2021-09-10T16:57:15.373Z","updated_at":"2025-02-25T15:35:16.395Z","phase":"Phase 1","brief_title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05039801","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2","pipe":" | ","alterations":" PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-10"},{"id":"9e786c9b-5753-46e4-84c2-5d48fa205166","acronym":"","url":"https://clinicaltrials.gov/study/NCT04953104","created_at":"2021-07-07T12:53:55.344Z","updated_at":"2025-02-25T17:37:12.423Z","phase":"Phase 2","brief_title":"ARID1A and/or KDM6A Mutation and CXCL13 Expression","source_id_and_acronym":"NCT04953104","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ARID1A • CXCL13","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A • CXCL13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/21/2021","start_date":" 09/21/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-29"},{"id":"7d21338e-ff73-41cf-853f-9516a337a92e","acronym":"FIH","url":"https://clinicaltrials.gov/study/NCT04104776","created_at":"2021-08-13T14:52:51.135Z","updated_at":"2025-02-25T15:43:41.485Z","phase":"Phase 1/2","brief_title":"A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas","source_id_and_acronym":"NCT04104776 - FIH","lead_sponsor":"Constellation Pharmaceuticals","biomarkers":" MSI • ARID1A • BAP1","pipe":" | ","alterations":" MSI-H/dMMR • ARID1A mutation","tags":["MSI • ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • tulmimetostat (DZR123)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 09/18/2019","start_date":" 09/18/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-08-02"},{"id":"a42b730f-7cb0-4a7e-b9c9-5253a2b3eeb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04390737","created_at":"2022-05-12T19:53:40.351Z","updated_at":"2024-07-02T16:35:04.605Z","phase":"Phase 1/2","brief_title":"Evaluate the Safety and Clinical Activity of HH2853","source_id_and_acronym":"NCT04390737","lead_sponsor":"Haihe Biopharma Co., Ltd.","biomarkers":" ARID1A • BAP1","pipe":" | ","alterations":" ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation","tags":["ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HH2853"],"overall_status":"Recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-09"},{"id":"ae2fbbdf-1d9d-47eb-9888-dad360517475","acronym":"MATRIX","url":"https://clinicaltrials.gov/study/NCT05986071","created_at":"2023-08-14T15:09:50.416Z","updated_at":"2025-02-25T16:19:00.084Z","phase":"Phase 1/2","brief_title":"I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers","source_id_and_acronym":"NCT05986071 - MATRIX","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1","pipe":" | ","alterations":" HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation","tags":["HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • tuvusertib (M1774)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 10/15/2027","study_completion_date":" 10/15/2027","last_update_posted":"2024-03-29"},{"id":"61e35a9f-0147-4909-988b-bb6eb21f1f94","acronym":"ARID1A","url":"https://clinicaltrials.gov/study/NCT05523440","created_at":"2022-08-31T15:56:57.793Z","updated_at":"2025-02-25T13:13:09.058Z","phase":"Phase 2","brief_title":"Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation","source_id_and_acronym":"NCT05523440 - ARID1A","lead_sponsor":"University of Oklahoma","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-15"},{"id":"b8eb8a0a-df83-4304-acfc-8e3aecd958e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04957615","created_at":"2021-07-12T15:52:53.983Z","updated_at":"2024-07-02T16:35:19.926Z","phase":"Phase 2","brief_title":"Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression","source_id_and_acronym":"NCT04957615","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/21/2021","start_date":" 09/21/2021","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-02-09"},{"id":"f3fa543f-eaf5-4acd-a3d9-1a89668bc625","acronym":"","url":"https://clinicaltrials.gov/study/NCT03568656","created_at":"2021-01-18T17:33:48.014Z","updated_at":"2024-07-02T16:35:22.821Z","phase":"Phase 1/2","brief_title":"Study to Evaluate CCS1477 in Advanced Tumours","source_id_and_acronym":"NCT03568656","lead_sponsor":"CellCentric Ltd.","biomarkers":" MYC • AR • ARID1A • CREBBP","pipe":" | ","alterations":" ARID1A mutation • CREBBP mutation • EP300 mutation","tags":["MYC • AR • ARID1A • CREBBP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • CREBBP mutation • EP300 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Tecentriq (atezolizumab) • Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • inobrodib (CCS1477)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 07/23/2018","start_date":" 07/23/2018","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-01-19"},{"id":"2dd99279-9ac9-4f3f-9024-0d203f7d34e4","acronym":"NRG-GY014","url":"https://clinicaltrials.gov/study/NCT03348631","created_at":"2021-01-18T16:32:10.163Z","updated_at":"2024-07-02T16:35:29.997Z","phase":"Phase 2","brief_title":"Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer","source_id_and_acronym":"NCT03348631 - NRG-GY014","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ARID1A","pipe":" | ","alterations":" MSI-H/dMMR • ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 04/14/2023","primary_completion_date":" 04/14/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2023-11-08"},{"id":"ff7c1831-8767-420c-a63e-fc4a8e3a8271","acronym":"","url":"https://clinicaltrials.gov/study/NCT04042831","created_at":"2021-01-18T19:49:54.652Z","updated_at":"2024-07-02T16:35:33.579Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","source_id_and_acronym":"NCT04042831","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • BRCA • CHEK2 • RAD51 • ATR • BRIP1 • NBN • EMSY","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • BRCA • CHEK2 • RAD51 • ATR • BRIP1 • NBN • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/24/2020","start_date":" 06/24/2020","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2023-10-13"},{"id":"12b373a9-f27e-4aa8-b2c5-2cb259826f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03718091","created_at":"2021-01-18T18:13:18.198Z","updated_at":"2024-07-02T16:35:43.598Z","phase":"Phase 2","brief_title":"M6620 (VX-970) in Selected Solid Tumors","source_id_and_acronym":"NCT03718091","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2023-07-07"},{"id":"afa91b8a-c52c-483b-b37d-dc401dac8395","acronym":"","url":"https://clinicaltrials.gov/study/NCT05023655","created_at":"2021-08-26T12:53:15.117Z","updated_at":"2024-07-02T16:35:50.284Z","phase":"Phase 2","brief_title":"Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation","source_id_and_acronym":"NCT05023655","lead_sponsor":"Prisma Health-Upstate","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/06/2022","start_date":" 01/06/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-04-18"},{"id":"58449b51-d1f8-458f-8290-5350013047d8","acronym":"MS201922-0001","url":"https://clinicaltrials.gov/study/NCT02278250","created_at":"2021-01-18T10:43:33.755Z","updated_at":"2025-02-25T16:14:08.887Z","phase":"Phase 1","brief_title":"First in Human Study of M4344 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02278250 - MS201922-0001","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" ARID1A • ATRX","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gartisertib (M4344)"],"overall_status":"Completed","enrollment":" Enrollment 97","initiation":"Initiation: 01/26/2015","start_date":" 01/26/2015","primary_txt":" Primary completion: 06/16/2021","primary_completion_date":" 06/16/2021","study_txt":" Completion: 09/24/2021","study_completion_date":" 09/24/2021","last_update_posted":"2023-03-16"},{"id":"6c581b08-736b-4d00-b039-553e8fb062bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05690035","created_at":"2023-01-19T14:59:36.781Z","updated_at":"2024-07-02T16:35:56.891Z","phase":"Phase 2","brief_title":"Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer","source_id_and_acronym":"NCT05690035","lead_sponsor":"Sun Yat-sen University","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-01-27"},{"id":"c66f765b-84b8-4be7-b6e5-f176047b0b9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633902","created_at":"2021-01-19T20:37:04.111Z","updated_at":"2024-07-02T16:35:59.576Z","phase":"Phase 2","brief_title":"Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation","source_id_and_acronym":"NCT04633902","lead_sponsor":"California Pacific Medical Center Research Institute","biomarkers":" BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation","tags":["BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-12-06"},{"id":"de090239-ac97-4a09-a8c1-e09e9af7bef0","acronym":"LUDOC II","url":"https://clinicaltrials.gov/study/NCT02518256","created_at":"2021-01-18T12:10:09.769Z","updated_at":"2024-07-02T16:36:04.422Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity","source_id_and_acronym":"NCT02518256 - LUDOC II","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 270","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-06"},{"id":"50472ebf-13f3-4a6d-abc3-8b39f9bfd5ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04611139","created_at":"2021-01-19T20:32:44.176Z","updated_at":"2025-02-25T16:10:47.159Z","phase":"Phase 1","brief_title":"Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers","source_id_and_acronym":"NCT04611139","lead_sponsor":"HonorHealth Research Institute","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • seclidemstat (SP2577)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-03-01"},{"id":"eb1cce54-97f6-48d4-8e71-c0f921263e6a","acronym":"CPMC17-MEL01","url":"https://clinicaltrials.gov/study/NCT03925350","created_at":"2021-01-18T19:18:35.366Z","updated_at":"2025-02-25T13:18:57.286Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation","source_id_and_acronym":"NCT03925350 - CPMC17-MEL01","lead_sponsor":"California Pacific Medical Center Research Institute","biomarkers":" BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • ATRX • BRCA • CHEK2 • RAD51 • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B","pipe":" | ","alterations":" ATM mutation • ARID1A mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • ATRX • BRCA • CHEK2 • RAD51 • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2021-10-22"},{"id":"e7ed921b-0c40-43f6-bd5a-19e029fa28c7","acronym":"BENEFIT","url":"https://clinicaltrials.gov/study/NCT04315155","created_at":"2021-01-18T20:54:51.245Z","updated_at":"2025-02-25T14:29:10.149Z","phase":"Phase 1","brief_title":"Evaluating Safety \u0026 Efficacy Belinostat Combo w Nivo Alone \u0026 w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation","source_id_and_acronym":"NCT04315155 - BENEFIT","lead_sponsor":"University of Utah","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Beleodaq (belinostat)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2020-10-28"},{"id":"4236f720-9ba7-4013-a8ae-9b0ed6db310d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04284202","created_at":"2021-01-18T20:47:51.975Z","updated_at":"2024-07-02T16:36:49.615Z","phase":"Phase 2","brief_title":"PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC","source_id_and_acronym":"NCT04284202","lead_sponsor":"The Affiliated Hospital of Qingdao University","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2020","start_date":" 03/01/2020","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-02-25"},{"id":"8e96cc7a-6dec-4aa5-96fd-2012bb5fe9bb","acronym":"LUDOC","url":"https://clinicaltrials.gov/study/NCT02062697","created_at":"2021-01-18T09:30:05.355Z","updated_at":"2024-07-02T16:36:49.646Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.","source_id_and_acronym":"NCT02062697 - LUDOC","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2020-02-25"}]